OBJECTIVE: To test the a priori hypothesis that acute and chronic work exposures to the World Trade Center (WTC) site on or after September 11, 2001 were associated with risk of new-onset systemic autoimmune diseases. METHODS: A nested case-control study was performed in WTC rescue/recovery workers who had received a rheumatologist-confirmed systemic autoimmune disease diagnosis between September 12, 2001 and September 11, 2013 (n = 59), each of whom was individually matched to 4 randomly selected controls (n = 236) on the basis of year of hire (±1 year), sex, race, and work assignment (firefighter or emergency medical service). Acute exposure was defined according to the earliest time of arrival (morning of 9/11 versus later) at the WTC site, and chronic exposure was defined as duration (number of months) of WTC site-related work. Rheumatologists were blinded with regard to each subject's exposure status. The conditional odds ratios (CORs) with 95% confidence intervals (95% CIs) for incident autoimmune disease were derived from exact conditional logistic regression models. RESULTS: Rheumatoid arthritis was the most common autoimmune diagnosis (37% of subjects), followed by spondyloarthritis (22%), inflammatory myositis (14%), systemic lupus erythematosus (12%), systemic sclerosis (5%), Sjögren's syndrome (5%), antiphospholipid syndrome (3%), and granulomatosis with polyangiitis (Wegener's) (2%). The COR for incident autoimmune disease increased by 13% (COR 1.13, 95% CI 1.02-1.26) for each additional month worked at the WTC site. These odds were independent of the association between high acute exposure (working during the morning of 9/11) and disease outcome, which conveyed an elevated, but not statistically significant, risk (COR 1.85, 95% CI 0.86-3.89). CONCLUSION: Prolonged work at the WTC site, independent of acute exposure, was an important predictor of post-9/11 systemic autoimmune diseases. The WTC Health Program should expand surveillance efforts for those with extended exposures, as early detection can facilitate early treatment, which has been shown to minimize organ damage and improve quality of life.
OBJECTIVE: To test the a priori hypothesis that acute and chronic work exposures to the World Trade Center (WTC) site on or after September 11, 2001 were associated with risk of new-onset systemic autoimmune diseases. METHODS: A nested case-control study was performed in WTC rescue/recovery workers who had received a rheumatologist-confirmed systemic autoimmune disease diagnosis between September 12, 2001 and September 11, 2013 (n = 59), each of whom was individually matched to 4 randomly selected controls (n = 236) on the basis of year of hire (±1 year), sex, race, and work assignment (firefighter or emergency medical service). Acute exposure was defined according to the earliest time of arrival (morning of 9/11 versus later) at the WTC site, and chronic exposure was defined as duration (number of months) of WTC site-related work. Rheumatologists were blinded with regard to each subject's exposure status. The conditional odds ratios (CORs) with 95% confidence intervals (95% CIs) for incident autoimmune disease were derived from exact conditional logistic regression models. RESULTS:Rheumatoid arthritis was the most common autoimmune diagnosis (37% of subjects), followed by spondyloarthritis (22%), inflammatory myositis (14%), systemic lupus erythematosus (12%), systemic sclerosis (5%), Sjögren's syndrome (5%), antiphospholipid syndrome (3%), and granulomatosis with polyangiitis (Wegener's) (2%). The COR for incident autoimmune disease increased by 13% (COR 1.13, 95% CI 1.02-1.26) for each additional month worked at the WTC site. These odds were independent of the association between high acute exposure (working during the morning of 9/11) and disease outcome, which conveyed an elevated, but not statistically significant, risk (COR 1.85, 95% CI 0.86-3.89). CONCLUSION: Prolonged work at the WTC site, independent of acute exposure, was an important predictor of post-9/11 systemic autoimmune diseases. The WTC Health Program should expand surveillance efforts for those with extended exposures, as early detection can facilitate early treatment, which has been shown to minimize organ damage and improve quality of life.
Authors: Carey B Maslow; Stephen M Friedman; Parul S Pillai; Joan Reibman; Kenneth I Berger; Roberta Goldring; Steven D Stellman; Mark Farfel Journal: Am J Public Health Date: 2012-04-19 Impact factor: 9.308
Authors: Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope Journal: Arthritis Rheum Date: 2013-10-03
Authors: Mayris P Webber; Michelle S Glaser; Jessica Weakley; Jackie Soo; Fen Ye; Rachel Zeig-Owens; Michael D Weiden; Anna Nolan; Thomas K Aldrich; Kerry Kelly; David Prezant Journal: Am J Ind Med Date: 2011-09 Impact factor: 2.214
Authors: Xia Jiang; Leendert A Trouw; Tineke J van Wesemael; Jing Shi; Camilla Bengtsson; Henrik Källberg; Vivi Malmström; Lena Israelsson; Hulda Hreggvidsdottir; Willem Verduijn; Lars Klareskog; Lars Alfredsson; Tom W J Huizinga; Rene E M Toes; Karin Lundberg; Diane van der Woude Journal: Ann Rheum Dis Date: 2014-05-08 Impact factor: 19.103
Authors: Mayris P Webber; Jackson Gustave; Roy Lee; Justin K Niles; Kerry Kelly; Hillel W Cohen; David J Prezant Journal: Environ Health Perspect Date: 2009-02-11 Impact factor: 9.031
Authors: Robin Herbert; Jacqueline Moline; Gwen Skloot; Kristina Metzger; Sherry Baron; Benjamin Luft; Steven Markowitz; Iris Udasin; Denise Harrison; Diane Stein; Andrew Todd; Paul Enright; Jeanne Mager Stellman; Philip J Landrigan; Stephen M Levin Journal: Environ Health Perspect Date: 2006-12 Impact factor: 9.031
Authors: Mark Farfel; Laura DiGrande; Robert Brackbill; Angela Prann; James Cone; Stephen Friedman; Deborah J Walker; Grant Pezeshki; Pauline Thomas; Sandro Galea; David Williamson; Thomas R Frieden; Lorna Thorpe Journal: J Urban Health Date: 2008-09-11 Impact factor: 3.671
Authors: Ayodeji Adegunsoye; Justin M Oldham; Carley Demchuk; Steven Montner; Rekha Vij; Mary E Strek Journal: Respir Med Date: 2016-03-21 Impact factor: 3.415
Authors: Jonathan E Leeman; Sean M McBride; Daniel Spielsinger; Eric J Sherman; Richard Wong; Nadeem Riaz; Nancy Y Lee; Chiaojung Jillian Tsai Journal: Int J Cancer Date: 2018-02-10 Impact factor: 7.396
Authors: Mayris P Webber; William Moir; Cynthia S Crowson; Hillel W Cohen; Rachel Zeig-Owens; Charles B Hall; Jessica Berman; Basit Qayyum; Nadia Jaber; Eric L Matteson; Yang Liu; Kerry Kelly; David J Prezant Journal: Mayo Clin Proc Date: 2015-12-09 Impact factor: 7.616
Authors: Eleanor M Summerhill; Gary W Hoyle; Sven-Eric Jordt; Bronwen J Jugg; James G Martin; Sadis Matalon; Steven E Patterson; David J Prezant; Alfred M Sciuto; Erik R Svendsen; Carl W White; Livia A Veress Journal: Ann Am Thorac Soc Date: 2017-06
Authors: Ingrid E Lundberg; Manabu Fujimoto; Jiri Vencovsky; Rohit Aggarwal; Marie Holmqvist; Lisa Christopher-Stine; Andrew L Mammen; Frederick W Miller Journal: Nat Rev Dis Primers Date: 2021-12-02 Impact factor: 52.329
Authors: F Scanzi; L Andreoli; M Martinelli; M Taraborelli; I Cavazzana; N Carabellese; R Ottaviani; F Allegri; F Franceschini; N Agmon-Levin; Y Shoenfeld; Angela Tincani Journal: Immunol Res Date: 2017-02 Impact factor: 4.505
Authors: Ariadne V Ebel; Gabrielle Lutt; Jill A Poole; Geoffrey M Thiele; Joshua F Baker; Grant W Cannon; Angelo Gaffo; Gail S Kerr; Andreas Reimold; Pascale Schwab; Namrata Singh; J Steuart Richards; Dana P Ascherman; Ted R Mikuls; Bryant R England Journal: Arthritis Rheumatol Date: 2021-01-29 Impact factor: 10.995